PTC Therapeutics

Yahoo Finance • 13 hours ago

PTC Therapeutics Investors Focus on Sephience Uptake, Huntington's Updates, RBC Says

PTC Therapeutics (PTCT) investors are expected to remain focused on the Sephience rollout for phenyl PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • yesterday

Principal Spectrum Preferred Secs Active ETF declares monthly distribution of $0.0827

* Principal Spectrum Preferred Secs Active ETF (PREF [https://seekingalpha.com/symbol/PREF]) - $0.0827 [https://www.principalam.com/fund/pref]. * Payable Dec 03, 2025; for shareholders of record Dec 01, 2025; ex-div Dec 01, 2025. MORE... Full story

Yahoo Finance • yesterday

Principal Investment Grade Corporate Active ETF declares monthly distribution of $0.0792

* Principal Investment Grade Corporate Active ETF (IG [https://seekingalpha.com/symbol/IG]) - $0.0792 [https://www.principalam.com/us/fund/ig]. * Payable Dec 03, 2025; for shareholders of record Dec 01, 2025; ex-div Dec 01, 2025. MORE... Full story

Yahoo Finance • 2 days ago

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J., Dec. 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 24, 2025 , the company approved non-statutory stock options to purchase an aggregate of 2,000 shares of its common stock and 8,20... Full story

Yahoo Finance • 3 days ago

PTC Therapeutics downgraded at RBC as Sephience sales priced in

[Wall Street sign with American flag in the background, symbolizing the financial heart of New York.] * RBC Capital Markets has downgraded PTC Therapeutics (PTCT [https://seekingalpha.com/symbol/PTCT]) to sector perform from outperform,... Full story

Yahoo Finance • 9 days ago

PTCT Crosses Above Average Analyst Target

In recent trading, shares of PTC Therapeutics Inc (Symbol: PTCT) have crossed above the average analyst 12-month target price of $54.17, changing hands for $55.13/share. When a stock reaches the target an analyst has set, the analyst logi... Full story

Yahoo Finance • 9 days ago

Sandisk Corp. To Replace Interpublic Group Of Companies In S&P 500

(RTTNews) - S&P Dow Jones Indices, a division of S&P Global (SPGI), announced that S&P SmallCap 600 constituent Sandisk Corp. (SNDK) will replace The Interpublic Group of Companies Inc. (IPG) in the S&P 500, and PTC Therapeutics Inc. (PTCT... Full story

Yahoo Finance • 9 days ago

Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600

NEW YORK, Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600: S&P SmallCap 600 constituent Sandisk Corp. (NASD: SNDK) will replace The Interpublic Group of Companies Inc. (... Full story

Yahoo Finance • 16 days ago

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally

Key Points New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares of Travere Therapeutics valu... Full story

Yahoo Finance • 29 days ago

PTC Therapeutics narrows 2025 revenue guidance to $750M–$800M as Sephience launch accelerates

Earnings Call Insights: PTC Therapeutics (PTCT) Q3 2025 MANAGEMENT VIEW * CEO Matthew Klein opened the call by highlighting "the initiation of the Sephience global launch in Europe and the United States" and described Sephience as "the... Full story

Yahoo Finance • 29 days ago

PTC Therapeutics GAAP EPS of $0.20, revenue of $211M beats by $35.48M

* PTC Therapeutics press release [https://seekingalpha.com/pr/20293018-ptc-therapeutics-provides-corporate-update-and-reports-third-quarter-2025-financial-results] (PTCT [https://seekingalpha.com/symbol/PTCT]): Q3 GAAP EPS of $0.20. *... Full story

Yahoo Finance • last month

Bank of America Securities Lifts PT on PTC Therapeutics (PTCT) to $87 From $76

PTC Therapeutics, Inc. (NASDAQ:PTCT) is one of the most profitable biotech stocks to buy. On October 20, Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on PTC Therapeutics, Inc. (NASDAQ:PTCT), lifting the price tar... Full story

Yahoo Finance • 2 months ago

Advanced Viral Delivery Systems Revolutionizing Gene Therapy for Neurological Disorders

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy on Neurological Diseases Market Report 2025" has been added to ResearchAndMarkets.com's offering. The gene therapy on neurological diseases market size has grown rapidly in... Full story

Yahoo Finance • 3 months ago

PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. PTC Therapeutics, Inc. is one of them. PTC Therapeutics, Inc. (NASDAQ:PTCT) is reinforcing its position in rare disease innovation with the... Full story

Yahoo Finance • 3 months ago

PTC THERAPEUTICS INC (NASDAQ:PTCT): An Affordable Growth Candidate in Biotech

Investors looking for growth chances at fair prices often consider methods like the "Affordable Growth" screen, which finds companies showing solid expansion possibility without high costs. This method balances the search for increasing re... Full story

Yahoo Finance • 3 months ago

PTC THERAPEUTICS INC (NASDAQ:PTCT) Emerges as a Top Affordable Growth Stock

Investors looking for growth openings often face the task of finding companies with solid expansion ability that have not yet become overpriced by the market. The Affordable Growth strategy handles this by filtering for stocks showing good... Full story

Yahoo Finance • 3 months ago

PTC Therapeutics CRL ‘expected,’ focus moves to Sephience, says RBC Capital

PTC Therapeutics (PTCT) on Tuesday announced that they received a complete response letter for vatiquinone in Friedreich’s ataxia, with the FDA stating that substantial evidence of efficacy was not demonstrated and that an additional adequ... Full story

Yahoo Finance • 4 months ago

Goldman Sachs reiterates Sell rating on PTC Therapeutics stock at $44 target

Investing.com - Goldman Sachs has reiterated its Sell rating and $44.00 price target on PTC Therapeutics (NASDAQ:PTCT), currently trading at $51.56 with a market capitalization of $4.1 billion, following the company’s receipt of a Comple... Full story

Yahoo Finance • 4 months ago

PTC Therapeutics stock falls as FDA issues CRL for vatiquinone in FA

Investing.com - PTC Therapeutics (NASDAQ:PTCT), a $4.1 billion market cap biotech company with an EXCELLENT financial health score according to InvestingPro, received a Complete Response Letter (CRL) from the FDA for vatiquinone in Fried... Full story

Yahoo Finance • 4 months ago

PTCT Makes Bullish Cross Above Critical Moving Average

In trading on Wednesday, shares of PTC Therapeutics Inc (Symbol: PTCT) crossed above their 200 day moving average of $47.62, changing hands as high as $49.10 per share. PTC Therapeutics Inc shares are currently trading up about 6.4% on th... Full story